WO2001079469A3 - Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses - Google Patents

Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses Download PDF

Info

Publication number
WO2001079469A3
WO2001079469A3 PCT/US2001/012053 US0112053W WO0179469A3 WO 2001079469 A3 WO2001079469 A3 WO 2001079469A3 US 0112053 W US0112053 W US 0112053W WO 0179469 A3 WO0179469 A3 WO 0179469A3
Authority
WO
WIPO (PCT)
Prior art keywords
corynebacteriaceae
histidine
histidine ammonia
ammonia lyase
cloning
Prior art date
Application number
PCT/US2001/012053
Other languages
French (fr)
Other versions
WO2001079469A2 (en
Inventor
Natarajan Sethuraman
Joseph Roberts
Thomas Macallister
Original Assignee
Univ South Carolina Res Found
Natarajan Sethuraman
Joseph Roberts
Thomas Macallister
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina Res Found, Natarajan Sethuraman, Joseph Roberts, Thomas Macallister filed Critical Univ South Carolina Res Found
Priority to AU2001257032A priority Critical patent/AU2001257032A1/en
Priority to CA002406390A priority patent/CA2406390A1/en
Priority to JP2001577453A priority patent/JP2003530850A/en
Priority to EP01930503A priority patent/EP1280924A2/en
Publication of WO2001079469A2 publication Critical patent/WO2001079469A2/en
Publication of WO2001079469A3 publication Critical patent/WO2001079469A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y403/00Carbon-nitrogen lyases (4.3)
    • C12Y403/01Ammonia-lyases (4.3.1)
    • C12Y403/01003Histidine ammonia-lyase (4.3.1.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Histidine ammonia lyase (HAL) isolated from Corynebacteriaceae can decrease serum histidine levels, induce accumulation of urocanic acid, and is not inhibited by L-histidinol. As a result, histidine ammonia lyases similar to the one isolated from Corynebacteriaceae are uniquely suitable for combination therapy with L-histidinol to treat histidine- and/or histamine-dependent pathologies, for example, infectious viruses, such as human Respiratory Syncytial Virus (RSV), Herpes Simplex Virus (HSV), and Human Immunodeficiency Virus (HIV), as well as cancers.
PCT/US2001/012053 2000-04-14 2001-04-13 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses WO2001079469A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001257032A AU2001257032A1 (en) 2000-04-14 2001-04-13 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
CA002406390A CA2406390A1 (en) 2000-04-14 2001-04-13 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
JP2001577453A JP2003530850A (en) 2000-04-14 2001-04-13 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
EP01930503A EP1280924A2 (en) 2000-04-14 2001-04-13 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19777000P 2000-04-14 2000-04-14
US60/197,770 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001079469A2 WO2001079469A2 (en) 2001-10-25
WO2001079469A3 true WO2001079469A3 (en) 2002-05-10

Family

ID=22730684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012053 WO2001079469A2 (en) 2000-04-14 2001-04-13 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses

Country Status (6)

Country Link
US (2) US6939541B2 (en)
EP (1) EP1280924A2 (en)
JP (1) JP2003530850A (en)
AU (1) AU2001257032A1 (en)
CA (1) CA2406390A1 (en)
WO (1) WO2001079469A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7181608B2 (en) * 2000-02-03 2007-02-20 Realtime Data Llc Systems and methods for accelerated loading of operating systems and application programs
JP2003289869A (en) * 2002-04-02 2003-10-14 Tosoh Corp Oligonucleotide for assaying mycobacterium avium as atypical acid-fast bacterium, and method for detecting the same
FI20031793A0 (en) * 2003-12-09 2003-12-09 Lasse Leino New anti-proliferative pharmaceutical composition
US7553653B2 (en) * 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US20110027346A1 (en) * 2006-06-02 2011-02-03 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2582459T3 (en) 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Compositions of phenylalanine ammonia-lyase variants of prokaryotes and methods of using their compositions
WO2017150304A1 (en) * 2016-02-29 2017-09-08 長瀬産業株式会社 Fermentation product of ergothioneine
CN109673548B (en) * 2018-12-29 2021-08-06 汕头大学 Application of urocanic acid in preparation of anti-white spot syndrome virus preparation
WO2023283558A1 (en) * 2021-07-08 2023-01-12 Regeneron Pharmaceuticals, Inc. Methods of treating skin cancer with histidine ammonia-lyase (hal) agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4955857A (en) * 1988-07-18 1990-09-11 Shettigar Udipi R Multi-enzyme bioreactor therapy for cancer
ES2063574T3 (en) * 1990-12-17 1995-01-01 Univ Manitoba IMPROVED TREATMENT METHOD FOR CANCER.
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAND L M ET AL: "HISTIDINE AMMONIA LYASE EC-4.3.1.3 FROM RAT LIVER PURIFICATION PROPERTIES AND INHIBITION BY SUBSTRATE ANALOGS", BIOCHEMISTRY, vol. 15, no. 9, 1976, pages 1814 - 1821, XP002188387, ISSN: 0006-2960 *
DE FABO E C ET AL: "Altered skin cytokine environment after UVB irradiation in UCA-deficient histidinemic C57BL/6-HalEdi mice.", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 69, no. SPEC. ISSUE., June 1999 (1999-06-01), Twenty Seventh Annual Meeting of the American Society for Photobiology;Washington, D.C., USA; July 10-15,1999, pages 18S - 19S, XP001053095, ISSN: 0031-8655 *
ROBERTS J ET AL: "BIOLOGIC AND ANTI NEOPLASTIC EFFECTS OF ENZYME MEDIATED IN-VIVO DEPLETION OF L GLUTAMINE L TRYPTOPHAN AND L HISTIDINE", CANCER TREATMENT REPORTS, vol. 63, no. 6, 1979, pages 1045 - 1054, XP010309040, ISSN: 0361-5960 *
See also references of EP1280924A2 *
WU P-C ET AL: "PURIFICATION OF HISTIDASE FROM STREPTOMYCES-GRISEUS AND NUCLEOTIDE SEQUENCE OF THE HUTH STRUCTURAL GENE", JOURNAL OF BACTERIOLOGY, vol. 174, no. 5, 1992, pages 1647 - 1655, XP001053073, ISSN: 0021-9193 *
ZAHARKO D ET AL: "L HISTIDINOL PRECLINICAL THERAPEUTIC STUDIES IN COMBINATION WITH ANTITUMOR AGENTS AND PHARMACOKINETIC STUDIES IN MICE", CANCER RESEARCH, vol. 52, no. 13, 1992, pages 3604 - 3609, XP002188388, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2001257032A1 (en) 2001-10-30
EP1280924A2 (en) 2003-02-05
US6939541B2 (en) 2005-09-06
US20060034817A1 (en) 2006-02-16
JP2003530850A (en) 2003-10-21
WO2001079469A2 (en) 2001-10-25
US20020052038A1 (en) 2002-05-02
CA2406390A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
WO2001079469A3 (en) Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
NZ515392A (en) Respiratory syncytial virus replication inhibitors
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
ES2160046A1 (en) Antiviral medicaments
WO2004046159A8 (en) Antiviral nucleoside derivatives
HK1071379A1 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2001045737A3 (en) Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
IL112539A (en) Chloropyrimidine intermediates for preparing-2-aminopurine nucleoside analogues and their preparation
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
GB0004128D0 (en) Novel compounds
ATE508635T1 (en) VIRUS VECTORS AND THEIR USE IN THERAPEUTIC METHODS
YU33802A (en) Polycycloalkylpurines as adenosine receptor antagonists
WO2001045712A8 (en) Combinations of medicaments for treating viral diseases
WO2000023065A8 (en) Storable active substance concentrate with formoterol
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
EP0652011A4 (en) Prophylactic and remedy for viral diseases in respiratory tract.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
AU2001232556A1 (en) Pyrimidine compounds and their use as modulators of chemokine receptor activity
WO2000053167A3 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
MXPA04004621A (en) Nucleosides preparation thereof and use as inhibitors of rna viral polymerases.
WO2006043153A3 (en) Use of zinc and copper chelators for the treatment of viral diseases
WO2004052905A3 (en) Antiviral nucleoside derivatives
TR199900523T2 (en) Pharmaceutical compositions for the treatment of diseases of viral origin.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2406390

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 577453

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001930503

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001930503

Country of ref document: EP